Yourgene Health PLC COVID-19 update (7450J)
December 24 2020 - 1:00AM
UK Regulatory
TIDMYGEN
RNS Number : 7450J
Yourgene Health PLC
24 December 2020
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
COVID-19 update: approved provider for UK Government and r
esponse to new virus strain
Manchester, UK - 24 December 2020: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that Yourgene
Genomic Services has been added to the UK Government's approved
COVID-19 private testing providers list for the Test to Release for
International Travel scheme introduced on 15 December 2020 ("Test
to Release"), and also for general coronavirus testing. The Company
has also conducted in silico analysis studies into the effect of
the new virus strain which suggests that the performance of its
test will be unaffected.
The Test to Release scheme is a UK Government backed programme,
designed to reduce quarantine periods for travellers arriving in
the UK. The Group is waiting for the government website to be
updated to reflect this in due course. Through the Test to Release
scheme, passengers have the opportunity to pay for a COVID-19 test
through the list of approved private providers, to find out if they
are able to reduce the self-isolation period after international
travel. Yourgene Genomic Services has the full COVID-19 testing
service offering required to meet the Department of Health &
Social Care's 15 minimum standards*. Yourgene will go live with the
Test to Release scheme in early January 2021 but the general
coronavirus testing offering is already live.
Following the announcement of a new virulent strain of
SARS-CoV-2 by the UK's COVID-19 Genomics UK consortium, known as
VUI-202012/01, Yourgene has conducted preliminary in silico
(computer) analysis of the mutations in this new variant to assess
the reliability of the Company's existing Clarigene(R) product.
Unlike some other tests on the market, the Clarigene(R) SARS-CoV-2
assay does not rely on amplification of the S gene, where one of
the key VUI-202012/01 variants (N501Y) is located and the results
of the in silico analysis suggest that the performance of the
Clarigene(R) assay will be unaffected by these mutations in
VUI-202012/01. For further customer assurance the Company is
conducting additional 'wet lab' testing to confirm the in silico
findings.
Lyn Rees, CEO of Yourgene Health plc, said: "We are extremely
pleased to be an approved private provider for the Test to Release
scheme to support international travel to the UK, as well as more
general UK COVID-19 testing. This approval confirms the high
standards and service levels we have been setting for our COVID-19
testing partners and in our wider Genomic Services laboratory
offering. We continue to monitor the evolving situation in order to
remain at the forefront of fighting the pandemic, and to expand our
capabilities in a way that accelerates our wider business
strategy."
*More information on the minimum standards set out by the
Department of Health & Social Care can be found here:
https://bit.ly/3pfSDnZ
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014. The Directors of the
Company take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDDXLFLBLLBFBF
(END) Dow Jones Newswires
December 24, 2020 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024